Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 18–19

HOS-108902 · Präparat HOS-093083

18 Delamanid (100 mg BID) Delamanid: Due to the risk of QTc prolongation AUC: ↑ 22% associated with DM-6705, if (Lopinavir/ritonavir co-administration of delamanid 400/100 mg BID) DM-6705 (delamanid active with Kaletra is considered metabolite): necessary, very frequent ECG AUC: ↑ 30% monitoring throughout the full delamanid treatment period is A more pronounced effect on recommended (see section 4.4 and DM-6705 exposure may be refer to the delamanid SmPC). observed during prolonged co- administration with lopinavir/ritonavir. Rifabutin, 150 mg QD Rifabutin (parent drug and active When given with Kaletra the 25-O-desacetyl metabolite): recommended dose of rifabutin is AUC: ↑ 5.7-fold 150 mg 3 times per week on set Cmax: ↑ 3.5-fold days (for example Monday- Wednesday-Friday). Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin. Further dosage reduction of rifabutin to 150 mg twice weekly on set days is recommended for patients in whom the 150 mg dose 3 times per week is not tolerated. It should be kept in mind that the twice weekly dosage of 150 mg may not provide an optimal exposure to rifabutin thus leading to a risk of rifamycin resistance and a treatment failure. No dose adjustment is needed for Kaletra.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262)